InteRNA is building a diversified product pipeline with a focus on lead drug candidate INT-1B3. INT-1B3 is a LNP-formulated, chemically modified miRNA mimic inducing apoptosis through caspase activation and PARP cleavage. In addition, INT-1B3 regulates the adenosine-A2A receptor pathway (through regulation of ATP->adenosine converting enzymes CD39 and CD73), inhibiting the escape from immune surveillance, and in parallel makes immune ‘cold’ tumors ‘hot’ through recruitment of CD8+ Teff cells and downregulation of LAG-3/FoxP3 Treg cells. Its MoA further encompasses regulation of CyclinD1, Mcl-1, K-Ras, c-Kit and TIM-3.
We aim to initially develop INT-1B3 for treatment of patients with hepatocellular carcinoma (HCC). Yet the compound also qualifies for melanoma, triple-negative breast cancer (TNBC) and lung cancer (NSCLC). In HCC, INT-1B3 may be positioned for 2nd line treatment of sorafenib-resistant HCC patients, or as 1st line treatment in combination with sorafenib.
Other programs encompass miRNA drug candidates for renal cell cancer (RCC), head and neck cancer (HNSCC), pancreatic and prostate cancer, and back-up candidates for HCC, melanoma and NSCLC.